Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RAPT Stock Forecast 2026-2027
$34.40
Current Price
$953.25M
Market Cap
Buy 10
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to RAPT Price Targets
+176.2%
To High Target of $95.00
+100.6%
To Median Target of $69.00
+62.8%
To Low Target of $56.00
RAPT Price Momentum
+6.1%
1 Week Change
-6.5%
1 Month Change
+290.9%
1 Year Change
+1.6%
Year-to-Date Change
-18.9%
From 52W High of $42.39
+507.3%
From 52W Low of $5.66
📊 TOP ANALYST CALLS
Did RAPT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if RAPT Therapeutics is one of their latest high-conviction picks.
Latest RAPT Stock Price Targets & Analyst Predictions
Based on our analysis of 21 Wall Street analysts, RAPT has a bullish consensus with a median price target of $69.00 (ranging from $56.00 to $95.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $34.40, the median forecast implies a 100.6% upside. This outlook is supported by 10 Buy, 1 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Etzer Darout at Barclays, suggesting a 62.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RAPT Analyst Ratings
10
Buy
1
Hold
0
Sell
RAPT Price Target Range
Low
$56.00
Average
$69.00
High
$95.00
Current: $34.40
Latest RAPT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RAPT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 18, 2025 | TD Cowen | Yaron Werber | Buy | Initiates | $N/A |
| Nov 12, 2025 | JP Morgan | Anupam Rama | Overweight | Maintains | $57.00 |
| Nov 7, 2025 | Barclays | Etzer Darout | Overweight | Maintains | $56.00 |
| Nov 3, 2025 | Wells Fargo | Yanan Zhu | Overweight | Maintains | $72.00 |
| Oct 27, 2025 | Guggenheim | Yatin Suneja | Buy | Initiates | $70.00 |
| Oct 27, 2025 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $72.00 |
| Oct 21, 2025 | Wells Fargo | Yanan Zhu | Overweight | Maintains | $48.00 |
| Oct 21, 2025 | Clear Street | Kaveri Pohlman | Buy | Maintains | $60.00 |
| Oct 21, 2025 | Barclays | Etzer Darout | Overweight | Maintains | $58.00 |
| Oct 20, 2025 | JP Morgan | Anupam Rama | Overweight | Upgrade | $55.00 |
| Oct 13, 2025 | Barclays | Etzer Darout | Overweight | Initiates | $35.00 |
| Sep 30, 2025 | Clear Street | Kaveri Pohlman | Buy | Maintains | $41.00 |
| Sep 26, 2025 | Leerink Partners | Thomas Smith | Outperform | Upgrade | $37.00 |
| Aug 12, 2025 | UBS | Eliana Merle | Neutral | Maintains | $9.00 |
| Aug 8, 2025 | Wells Fargo | Yanan Zhu | Overweight | Maintains | $38.00 |
| Jul 30, 2025 | JP Morgan | Anupam Rama | Neutral | Upgrade | $14.00 |
| Jul 22, 2025 | LifeSci Capital | Outperform | Initiates | $31.00 | |
| Jul 10, 2025 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $27.00 |
| May 22, 2025 | HC Wainwright & Co. | Emily Bodnar | Buy | Assumes | $6.00 |
| May 22, 2025 | UBS | Eliana Merle | Neutral | Maintains | $1.00 |
RAPT Therapeutics, Inc. (RAPT) Competitors
The following stocks are similar to RAPT Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
RAPT Therapeutics, Inc. (RAPT) Financial Data
RAPT Therapeutics, Inc. has a market capitalization of $953.25M with a P/E ratio of -1.3x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -85.4%.
Valuation Metrics
Market Cap
$953.25M
Enterprise Value
$798.51M
P/E Ratio
-1.3x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+16.5%
Current Ratio
12.0x
Debt/Equity
1.7x
ROE
-85.4%
ROA
-51.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
RAPT Therapeutics, Inc. (RAPT) Business Model
About RAPT Therapeutics, Inc.
What They Do
Develops therapies for inflammatory and immunologic diseases.
Business Model
RAPT Therapeutics operates as a clinical-stage biopharmaceutical company, focusing on the discovery and development of innovative therapies targeting immune system responses. The company generates revenue through the advancement of its drug candidates, including monoclonal antibodies and small molecule antagonists, aimed at treating conditions like food allergies, chronic urticaria, and various cancers.
Additional Information
RAPT's pipeline includes RPT904 and CCR4 antagonists, reflecting its commitment to addressing unmet medical needs in immunology and oncology. The company's proprietary expertise in immunology positions it well to create novel treatments that could significantly impact patients' lives.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
60
CEO
Dr. Brian Russell Wong M.D., Ph.D.
Country
United States
IPO Year
N/A
Website
www.rapt.comRAPT Therapeutics, Inc. (RAPT) Latest News & Analysis
Latest News
Quick Summary
RAPT Therapeutics, a clinical-stage biopharmaceutical company, announced Brian Wong, M.D. as part of its leadership on January 7, 2026. The company focuses on therapies for inflammatory diseases.
Why It Matters
RAPT Therapeutics' announcement of leadership changes can impact investor confidence and stock performance, influencing future development and commercialization of therapies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
RAPT Therapeutics: Strong Promise In Immunology, Looking Like An Opportunity At These Prices
1 month ago
Quick Summary
RAPT Therapeutics upgraded to 'Buy' amid promising phase 2 data for Ozureprubart in chronic urticaria and a strong cash position from a $250M offering, though cash burn risks persist.
Why It Matters
RAPT Therapeutics' upgrade to 'Buy' reflects strong pipeline progress and valuation appeal, while favorable trial data and cash reserves support growth, despite cash burn risks.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
RAPT Therapeutics initiated a Phase 2b trial for ozureprubart in food allergies and reported positive Phase 2 results in chronic spontaneous urticaria. The company completed a $250 million public offering.
Why It Matters
RAPT Therapeutics' advancements in clinical trials and a significant public offering enhance its growth potential, promising improved therapies for food allergies and chronic urticaria, impacting investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
RAPT Therapeutics will participate in Guggenheim's 2nd Annual Healthcare Innovation Conference on November 11, 2025, featuring a fireside chat at 3:30 p.m.
Why It Matters
RAPT Therapeutics' participation in investor conferences signals active engagement with the investment community, potentially influencing stock interest and market perception.
Source: GlobeNewsWire
Market Sentiment:
Neutral
RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies
2 months ago
Quick Summary
RAPT Therapeutics has initiated a Phase 2b clinical trial for ozureprubart, targeting IgE-mediated food allergies, following positive Phase 2 results in chronic spontaneous urticaria.
Why It Matters
RAPT Therapeutics' initiation of a Phase 2b trial for ozureprubart in food allergies signals potential market expansion, enhancing growth prospects and investor interest in the company's immunotherapy pipeline.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Rapt stock rose after the company reported its experimental hives treatment outperformed Roche's Xolair in a 16-week study.
Why It Matters
Rapt's stock surge indicates strong market confidence in its new treatment's potential over a major competitor, potentially leading to increased sales and market share.
Source: Investors Business Daily
Market Sentiment:
Positive
Frequently Asked Questions About RAPT Stock
What is RAPT Therapeutics, Inc.'s (RAPT) stock forecast for 2026?
Based on our analysis of 21 Wall Street analysts, RAPT Therapeutics, Inc. (RAPT) has a median price target of $69.00. The highest price target is $95.00 and the lowest is $56.00.
Is RAPT stock a good investment in 2026?
According to current analyst ratings, RAPT has 10 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $34.40. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RAPT stock?
Wall Street analysts predict RAPT stock could reach $69.00 in the next 12 months. This represents a 100.6% increase from the current price of $34.40. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is RAPT Therapeutics, Inc.'s business model?
RAPT Therapeutics operates as a clinical-stage biopharmaceutical company, focusing on the discovery and development of innovative therapies targeting immune system responses. The company generates revenue through the advancement of its drug candidates, including monoclonal antibodies and small molecule antagonists, aimed at treating conditions like food allergies, chronic urticaria, and various cancers.
What is the highest forecasted price for RAPT RAPT Therapeutics, Inc.?
The highest price target for RAPT is $95.00 from at , which represents a 176.2% increase from the current price of $34.40.
What is the lowest forecasted price for RAPT RAPT Therapeutics, Inc.?
The lowest price target for RAPT is $56.00 from Etzer Darout at Barclays, which represents a 62.8% increase from the current price of $34.40.
What is the overall RAPT consensus from analysts for RAPT Therapeutics, Inc.?
The overall analyst consensus for RAPT is bullish. Out of 21 Wall Street analysts, 10 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $69.00.
How accurate are RAPT stock price projections?
Stock price projections, including those for RAPT Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 13, 2026 8:42 PM UTC